Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden

Background: The paraoxonase gene cluster on chromosome 7 comprising the PON1–3 genes is an attractive candidate for association in amyotrophic lateral sclerosis (ALS) given the role of paraoxonase genes during the response to oxidative stress and their contribution to the enzymatic break down of nerve toxins. Oxidative stress is considered one of the mechanisms involved in ALS pathogenesis. Evidence for this includes the fact that mutations of SOD1, which normally reduce the production of toxic superoxide anion, account for 12% to 23% of familial cases in ALS. In addition, PON variants were shown to be associated with susceptibility to ALS in several North American and European populations. Methods: We extended this analysis to examine 20 single nucleotide polymorphisms (SNPs) across the PON gene cluster in a set of patients from France (480 cases, 475 controls), Quebec (159 cases, 95 controls), and Sweden (558 cases, 506 controls). Results: Although individual SNPs were not considered associated on their own, a haplotype of SNPs at the C-terminal portion of PON2 that includes the PON2 C311S amino acid change was significant in the French (p value 0.0075) and Quebec (p value 0.026) populations as well as all three populations combined (p value 1.69 × 10−6). Stratification of the samples showed that this variation was pertinent to ALS susceptibility as a whole, and not to a particular subset of patients. Conclusions: These findings contribute to the increasing weight of evidence that genetic variants in the paraoxonase gene cluster are associated with amyotrophic lateral sclerosis.

[1]  R. Ophoff,et al.  ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study , 2007, The Lancet Neurology.

[2]  Kuixing Zhang,et al.  Whole-genome analysis of sporadic amyotrophic lateral sclerosis. , 2007, The New England journal of medicine.

[3]  S. Cronin,et al.  Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  R. Trent,et al.  A gene-environment study of the paraoxonase 1 gene and pesticides in amyotrophic lateral sclerosis. , 2007, Neurotoxicology.

[5]  Sonja W. Scholz,et al.  Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data , 2007, The Lancet Neurology.

[6]  M. Małecki,et al.  Paraoxonase gene polymorphisms and sporadic ALS , 2006, Neurology.

[7]  J. Haines,et al.  Paraoxonase cluster polymorphisms are associated with sporadic ALS , 2006, Neurology.

[8]  S. Ennis,et al.  ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis , 2006, Nature Genetics.

[9]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[10]  C. Armon Excess incidence of ALS in young Gulf War veterans , 2004, Neurology.

[11]  M. Thun,et al.  Prospective study of cigarette smoking and amyotrophic lateral sclerosis. , 2004, American journal of epidemiology.

[12]  E. Trabetti,et al.  Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction , 2004, European journal of clinical investigation.

[13]  S. Grambow,et al.  Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations , 2003, Neurology.

[14]  F. Dudbridge Pedigree disequilibrium tests for multilocus haplotypes , 2003, Genetic epidemiology.

[15]  Y. Stern,et al.  Premorbid weight, body mass, and varsity athletics in ALS , 2002, Neurology.

[16]  S. Reddy,et al.  Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein* , 2001, The Journal of Biological Chemistry.

[17]  W. Longstreth,et al.  Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. , 2000, American journal of epidemiology.

[18]  J. Shefner,et al.  Association of Cigarette Smoking with Amyotrophic Lateral Sclerosis , 1999, Neuroepidemiology.

[19]  S. Scherer,et al.  Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. , 1998, Gene.

[20]  P. Andersen,et al.  Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase , 1995, Nature Genetics.

[21]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[22]  J. Slattery,et al.  Risk factors for motor neuron disease: a case-control study based on patients from the Scottish Motor Neuron Disease Register. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[23]  S. Adkins,et al.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.

[24]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[25]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[26]  W G Alvord,et al.  Familial Amyotrophic Lateral Sclerosis, 1850-1989: A Statistical Analysis of the World Literature , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[27]  Till Acker,et al.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.

[28]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.